Skip to main content

Sequenom Inks Agreement with Coventry for Coverage of T21 Test

NEW YORK (GenomeWeb News) – Sequenom today said that health insurance provider Coventry Health Care National Network will provide coverage for its T21 test.

According to Sequenom, the 2.2 million members of Coventry's First Health PPO network will have coverage for its MaterniT21 Plus testing service. The test, which detects for the presence of trisomy 21, 18, and 13, is performed at the firm's lab, the Sequenom Center for Molecular Medicine.

Last month, the firm announced an expanded agreement with healthcare cost management firm MultiPlan to include the MaterniT21 Plus LDT test in its offerings to its network of 900,000 providers.

Bethesda, Md.-based Coventry has more than 5 million members in all 50 states, as well as the District of Columbia and Puerto Rico.

In early Wednesday trade on the Nasdaq, shares of Sequenom were up around 5 percent at $5.07.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.